NCT07149961Completed
Curcumin-Piperine Supplementation in STEMI - SPICE STEMI Trial
Supplementation of Piperine and Curcumin (Curcuma Xanthorrhiza) Extract in ST Elevation Myocardial Infarction - SPICE STEMI Trial
Source: ClinicalTrials.gov · Last updated 2 Sept 2025
Brief summary (registry, in English)
This study aims to evaluate whether supplementation with a combination of curcumin and piperine can help reduce inflammation and oxidative stress in patients who have experienced a heart attack called ST-Elevation Myocardial Infarction (STEMI) and are undergoing a procedure known as primary percutaneous coronary intervention (PPCI). Curcumin, a natural compound from turmeric, is known for its antioxidant and anti-inflammatory effects, but it is not easily absorbed by the body. Piperine, a compound from black pepper, can improve curcumin absorption. By combining the two, we hope to maximize their potential benefits. The study will measure markers of inflammation (high-sensitivity C-reactive protein, hsCRP) and oxidative stress (malondialdehyde, MDA) at three time points: before treatment, shortly after the PPCI procedure, and after 28 days of supplementation. The main question is whether curcumin-piperine supplementation can provide additional protection against inflammation and oxidative stress compared to a placebo, potentially supporting recovery and reducing the risk of future heart problems.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 16 Aug 2025
- Start date
- 5 Feb 2025
- Primary completion date
- 25 Apr 2025
- Lead sponsor
- Universitas Diponegoro
- Diseases
- Coronary artery disease
- NCT number
- NCT07149961
What you commit to
- Study type: Interventional
- Participants enrolled: 50
- From 5 Feb 2025 to the primary completion date, 25 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Regular prior use of curcumin supplementation.
- History of prior myocardial infarction, previous percutaneous coronary intervention, or coronary artery bypass graft surgery.
Other illness
- Known hypersensitivity to curcumin or piperine.
- Active malignancy.
- Chronic infections (e.g., hepatitis, tuberculosis, or HIV).
Lab values
- Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² or rapidly declining renal function.
Other
- Hemodynamic instability or severe dyspnoea with clinical signs of congestion (elevated jugular venous pressure, pulmonary rales affecting \>1/3 of lung fields, hepatomegaly, ascites, or peripheral oedema).
Who the study is looking for
- Adults aged 18 to 80 years.
- Confirmed diagnosis of ST-Elevation Myocardial Infarction (STEMI). Symptom onset within 12 hours, or within 12 to 72 hours in cases with an indication for primary percutaneous coronary intervention (PPCI).
- Receiving standard-of-care medical therapy according to current guidelines, including:
- Dual antiplatelet therapy. Angiotensin-Converting Enzyme Inhibitors (ACE-i) or Angiotensin Receptor Blockers (ARBs).
- Statins. Beta-blockers.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitas Diponegoro Coordinator of this site? Confirm its status | Semarang | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.